Shionogi Company Limited

Hokkaido University

Shoichi Naito

Yoshito Numata

Junji Onoda

Shoji Yamane

Tatsuya Takahashi

Kazuhiko Maekawa

Katsutoshi Yamada

Tasuku Tsukamoto

Shin-Ichiro Nishimura

Naoki Ohyabu

Etsuo Nakamura

Sunao Imai

Hiroaki Aino

Akira Yamauchi

Keiko Kawamoto

Yasuhiko Sato

Hiroshi Hinou

Junji Kishono

Provided is a humanized monoclonal antibody or an antibody fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.

Method for the treatment or prevention of a disease related to vascular endothelial lipase by administering a humanized monoclonal antibody

Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.

Method of inhibiting the enzymatic activity of vascular endothelial lipase with a monoclonal antibody

Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase

Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase

Provided is a monoclonal antibody or a fragment thereof that selectively inhibits enzyme activity of EL and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.

Monoclonal antibody against EL which inhibits enzyme activity of EL

An objective of the present invention is to provide a MUC1 antibody having high specificity to cancer cells. The objective has been achieved by the present inventors who found that a cancer-specific sugar chain can be specifically recognized in MUC1 and a cancer cell expressing MUC1 having such a cancer cell specific sugar chain can be recognized. The present invention provides an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, having, for example, 40-fold specificity or more for a cancer-associated structure of MUC1 as compared to that of a normal tissue-associated structure of MUC1.

MUC1 antibody

An object of the present invention is to provide an antibody which does not bind to a normal cell, and is specific for a cancer cell. The object was solved by the finding by the present inventors that an antibody obtained by immunizing an animal using a 2,3ST glycopeptide as an antigen unexpectedly recognizes a sugar chain specific for a cancer specifically and remarkably, and consequently, can recognize and kill a cancer cell expressing MUC1 having such a cancer cell-specific sugar chain. The present invention provides, for example, an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, in which specificity for a cancer-associated structure of MUC1 is 100-fold or more as compared with that for a normal tissue-associated structure of MUC1.

Anti-MUC1 antibody

A neutralizing monoclonal antibody specifically reacting with MMP13, a method of neutralizing enzyme activity of MMP13 and an immunological measuring method each using the antibody, as well as a diagnostic agent and a pharmaceutical composition containing the antibody, are provided. Various antibodies to MMP13 have been hitherto obtained, but an antibody having neutralizing activity against MMP13 has not been obtained. The present inventors intensively studied, as a result, found out a neutralizing antibody having specificity for MMP13, resulting in completion of the present invention.

Monoclonal antibody having neutralizing activity against MMP13

Growing community of inventors

Toyonaka, Japan

Shoichi Naito